No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic and metabolic drivers of cancer and age-related disease, today announced favorable results from a comprehensive series of IND-enabling Good Laboratory Pract ...

Core Findings - Telomir Pharmaceuticals has expanded the oncology profile of its investigational compound Telomir-1 to include aggressive human leukemia cells, in addition to its previously reported efficacy in triple-negative breast cancer, pancreatic cancer, and aggressive prostate cancer models [1] Company Overview - Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing small-molecule therapies that target the epigenetic and metabolic roots of cancer, aging, and age-related diseases [1]

Financial Performance - Telomir Pharmaceuticals reported net losses of $1.1 million for Q3 2025, compared to $6.0 million for Q3 2024, and $8.4 million for the nine months ended September 30, 2025, down from $13.7 million in the same period of 2024[80]. - The company has not generated any revenue and expects expenses to increase substantially as it advances preclinical activities and initiates clinical trials[79]. - The company has not generated any revenue since inception and does not anticipate doing so until successful completion of preclinical and clinical development and obtaining regulatory approval[101]. - The company incurred $2.5 million in negative cash flow from operations for the nine months ended September 30, 2025, compared to $4.5 million in 2024[111]. - As of September 30, 2025, the company had cash and cash equivalents of approximately $7.3 million and an accumulated deficit of approximately $38.9 million[111]. - The company expects its cash and cash equivalents to fund operations only through the third quarter of 2026, raising substantial doubt about its ability to continue as a going concern[112]. Equity Financing - The company raised $3 million in equity financing through a direct investment, issuing 333,334 shares at $3.00 per share, an 18% premium to the closing price of $2.54 on the execution date[81]. - The company sold a total of 1,200,000 shares at an average price of $1.82 per share through its at-the-market equity offering facility[87]. - Financing activities provided $8.6 million of cash for the nine months ended September 30, 2025, primarily from the sale of common stock[119]. - The company entered into an agreement to raise $3 million in equity financing through a direct investment by The Bayshore Trust, issuing shares at a purchase price of $3.00 per share, representing an 18% premium to the closing share price on the date of execution[110]. Research and Development - Research and development expenses for the three months ended September 30, 2025, were $0.8 million, up from $0.6 million in the same period in 2024, primarily due to costs associated with the lead investigational therapy, Telomir-1[99]. - For the nine months ended September 30, 2025, research and development expenses totaled $1.1 million, a decrease from $1.9 million in the same period in 2024, attributed to certain pharmaceutical manufacturing activities not performed in 2025[100]. Product Development - A binding Letter of Intent was executed on October 17, 2025, to acquire TELI Pharmaceuticals, securing worldwide rights to Telomir-1, with potential contributions of up to $5 million from TELI shareholders[76][93]. - Telomir-1 demonstrated significant preclinical efficacy, including reversing DNA methylation of tumor suppressor genes and inhibiting aggressive cancer cell viability in various models[92][90]. - The company reported that Telomir-1 improved neuromotor performance and reduced liver-copper accumulation in a Wilson's disease model, indicating multi-organ protective effects[74]. - Telomir-1 showed the ability to restore mitochondrial function without triggering oxidative stress in human cells derived from a Progeria patient[84]. - Telomir-1's mechanism includes modulation of essential metal ions and epigenetic remodeling, which are believed to underlie aging, cancer, and metabolic dysfunction[75]. - Telomir-1 has not been evaluated in humans, and there is no assurance that preclinical results will translate into clinical safety or efficacy[75]. Administrative Expenses - General and administrative expenses for the three months ended September 30, 2025, were $0.4 million, down from $5.4 million in 2024, mainly due to stock-based compensation related to grants issued in 2024[105]. - For the nine months ended September 30, 2025, general and administrative expenses were $7.3 million, compared to $7.0 million in 2024, with the increase primarily due to executive stock-based compensation[105].

Core Insights - New findings indicate that Telomir-1 significantly impacts CASP8 and GSTP1, which are essential genes involved in regulating cell death and detoxification pathways often altered in cancer [1] Company Summary - Telomir Pharmaceuticals, Inc. is a pre-clinical biotechnology company focused on developing therapies that address the epigenetic causes of cancer, aging, and age-related diseases [1] - The company reported new preclinical data from an in vivo study involving mice with human aggressive prostate cancer tumors [1] Research Findings - The study evaluated DNA-methylation changes in the defense genes CASP8 and GSTP1 after treatment with oral Telomir-1, Rapamycin, chemotherapy, and combination regimens [1]

Core Insights - Telomir Pharmaceuticals, Inc. has executed a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., which will secure worldwide rights to its lead investigational therapy, Telomir-1 [1] - The agreement aims to unify global IP rights and enable up to $5 million in potential shareholder contributions, strengthening Telomir's foundation for partnerships, licensing, and long-term value creation [1] Company Overview - Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing therapies targeting epigenetic drivers of cancer, aging, and age-related diseases [1]

Core Insights - Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) has seen a significant increase in stock price, rising 20.30% to $1.98, with a trading volume of 21.60 million shares compared to the average of 4.9 million shares [1][5]. Group 1: Drug Candidate Performance - The lead drug candidate, Telomir-1, has demonstrated a significant reduction in the viability of aggressive triple-negative breast cancer (TNBC) cells in laboratory studies, showing a clear, dose-dependent effect [2]. - Telomir-1's efficacy is linked to its ability to regulate cellular iron and energy balance, as evidenced by the recovery of cancer cells when iron was reintroduced [2]. Group 2: Mechanism of Action - Telomir-1 has been shown to reset abnormal DNA methylation patterns and restore balanced gene expression in cancer models, particularly in TNBC where iron-dependent enzymes contribute to aggressive cancer behavior [3]. Group 3: Future Plans - The company plans to expand its research to include additional cancer types, such as pancreatic cancer and leukemia, and will conduct further animal studies in preparation for an Investigational New Drug (IND) submission [4].

Market Overview - U.S. equity markets are experiencing a slight pullback after a week of record gains, with major indices consolidating amidst optimism around AI and macroeconomic uncertainties, particularly the government shutdown [1][2][11] - The S&P 500 is down approximately 0.3% from its record close of 6,753.72, while the Nasdaq Composite also fell around 0.3% after reaching 23,043.38 [2] Sector Performance - Year-to-date, the S&P 500 has gained 14.8%, with technology leading the way, alongside Basic Materials and Communication Services, which have seen gains of 28.90% and 24.18% respectively [3] - Energy and financial stocks are stable, benefiting from stable oil prices and favorable interest rate prospects, although there are concerns about market overheating, particularly regarding the "Magnificent Seven" megacaps [3] Upcoming Economic Events - The U.S. government shutdown is ongoing, limiting key economic data releases, which has heightened investor focus on other market drivers [4] - The Federal Reserve is a focal point, with a high probability (around 95%) of an October rate cut anticipated, as revealed in the minutes from the September meeting [5] Earnings Season - The third-quarter earnings season has begun, with Delta Air Lines reporting record revenue and a positive outlook, leading to a stock surge of over 4% [6] - PepsiCo's stock rose by 3.5% after exceeding Q3 estimates and announcing a CFO change, while major banks are expected to report a 7.9% year-over-year earnings growth rate for the S&P 500 [6] Notable Stock Movements - Nvidia reached an all-time intraday high of $195.30, climbing nearly 3% after a price target increase by an analyst, driven by increased demand for computing [7] - Advanced Micro Devices rose over 11% following a significant deal with OpenAI, while Cisco unveiled a new product aimed at AI data centers [7][8] Commodities Market - Gold futures pulled back about 1% but remain above $4,000 per ounce, with a year-to-date increase of over 50% [10] - Silver hit $50 for the first time since 1980, marking a 60% year-to-date gain, while crude oil prices retreated slightly to $61.35 per barrel [10]

分组1 - Richardson Electronics, Ltd. reported better-than-expected first-quarter financial results, with earnings of 13 cents per share, surpassing the analyst consensus estimate of 1 cent per share [1] - The company achieved quarterly sales of $54.607 million, exceeding the analyst consensus estimate of $51.510 million [1] - Following the positive earnings report, Richardson Electronics shares increased by 20.2% to $12.76 in pre-market trading [1] 分组2 - Turn Therapeutics Inc. saw a significant gain of 226.3%, reaching $22.84 in pre-market trading after commencing trading on the Nasdaq Capital Market [5] - Baosheng Media Group Holdings Limited surged by 107.7% to $6.88 in pre-market trading [5] - Several other companies also experienced notable pre-market trading gains, including Alaunos Therapeutics, Inc. (+61.5%), Ambow Education Holding Ltd. (+53.2%), and AiRWA Inc. (+45.7%) [5]

Core Findings - Telomir Pharmaceuticals, Inc. announced new preclinical results indicating that its investigational therapy Telomir-1 can restore the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of key genes MASPIN and RASSF1A in aggressive prostate cancer models [1] Group 1: Company Overview - Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing therapies that target epigenetic drivers of cancer, aging, and age-related diseases [1] Group 2: Research Findings - Telomir-1 reactivates two critical tumor suppressor genes, MASPIN and RASSF1A, which are essential for blocking invasion, limiting metastasis, and improving chemotherapy responsiveness in prostate cancer [1]

Market Overview - U.S. stock futures declined on Tuesday following mixed movements on Monday, with major benchmark indices showing lower futures [1] - The Advanced Micro Devices Inc. (NASDAQ:AMD) deal with OpenAI contributed to a rally in AI-linked stocks, which has been a driving force behind Wall Street's bull run this year [1] Economic Indicators - The U.S. government shutdown, now in its seventh day, has delayed the release of the U.S. trade deficit data [2] - The 10-year Treasury bond yield is at 4.17%, while the two-year bond yield stands at 3.59% [2] - Market expectations indicate a 92.5% likelihood of the Federal Reserve cutting interest rates in its upcoming October meeting [2] Futures Performance - Dow Jones futures decreased by 0.18%, S&P 500 by 0.08%, Nasdaq 100 by 0.04%, and Russell 2000 by 0.13% [3] - The SPDR S&P 500 ETF Trust (NYSE:SPY) fell by 0.037% to $671.36, while Invesco QQQ Trust ETF (NASDAQ:QQQ) rose by 0.0099% to $607.77 in premarket trading [3] Stocks in Focus - Trilogy Metals Inc. (NYSE:TMQ) surged by 180.38% in premarket trading after the White House announced a $35.6 million investment for a 10% stake to support mining exploration in Alaska's Ambler Mining District [8] - Advanced Micro Devices Inc. (NASDAQ:AMD) increased by 2.57% following a deal with OpenAI to supply Instinct GPU accelerators for AI infrastructure [9] - Applovin Corp. (NASDAQ:APP) fell by 2.56% amid an SEC investigation into its data-collection practices [10] - Telomir Pharmaceuticals Inc. (NASDAQ:TELO) jumped by 30.99% after releasing promising preclinical study results for its lead compound [11] Analyst Insights - Corporate America is expected to deliver a strong earnings season for Q3 2025, with a forecasted low-teens earnings growth rate for the S&P 500 [16] - Factors contributing to this outlook include a resilient economy, strong AI investment, and a weaker U.S. dollar [17] - Analysts predict a 5% earnings beat above current consensus estimates for the third quarter, despite potential tariff pressures [18]